Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.400 Biomarker disease BEFREE Through double-immunohistochemical staining for platelet-derived growth factor receptor α (PDGFRα) and glial fibrillary acidic protein (GFAP), this study explored the intercase variability among 45 human GBM samples regarding density of GFAP+ peritumoral astrocytes and a subset of GFAP+ peritumoral astrocyte-like cells also expressing PDGFRα. 31769546 2020
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.400 AlteredExpression disease BEFREE Targeting PDGFRα-activated glioblastoma through specific inhibition of SHP-2-mediated signaling. 31232447 2019
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.400 GeneticVariation disease BEFREE In glioblastomas (n = 45), amplification of EGFR [18 (40%)], PDGFRA [3 (7%)], KIT [2 (4%)], MET [1 (2%)], and AKT1 [1 (2%)] was detected. 31000415 2019
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.400 Biomarker disease BEFREE It has been shown that the dysregulated receptor tyrosine kinase (RTK, including EGFR, MET, PDGFRα, ect.) signaling pathways have pivotal roles in the progression of gliomas, especially glioblastoma. 31221203 2019
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.400 Biomarker disease BEFREE In summary, our results show that well-tailored RNA aptamers targeting the PDGFRα-STAT3 axis have the potential to act as anti-cancer therapeutics in GBM. 30594071 2019
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.400 Biomarker disease BEFREE A PDGFRα-driven mouse model of glioblastoma reveals a stathmin1-mediated mechanism of sensitivity to vinblastine. 30082792 2018
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.400 Biomarker disease BEFREE Further analysis, including whole exome sequencing, revealed missense mutations or complex gene fusion events in PDGFRA with augmented expression in the secondary glioblastomas after radiotherapy, implicating PDGFRA as a putative driver in the development of secondary glioblastomas after treatment exposure. 29644394 2018
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.400 Biomarker disease BEFREE Labeling of PDGFRα in glioblastoma cells and tumor-associated stromal cells was highly variable, with no correlation with PFS. 27844311 2017
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.400 AlteredExpression disease BEFREE Additionally, ectopic expression of PDGFRα, NOS2, or ID4 activated the PDGF-NO-ID4-signaling circuit and enhanced the self-renewal of GBM cell lines. 28327358 2017
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.400 Biomarker disease BEFREE LTS GB showed frequent chromosomal gains in 4q12 (platelet derived growth factor receptor alpha and KIT) and 12q14.1 (cyclin-dependent kinase 4), and deletion in 19q13.33 (BAX, branched chain amino-acid transaminase 2, and cluster of differentiation 33). 27932423 2017
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.400 Biomarker disease BEFREE These results indicate that GBM growth responses to targeted therapies previously tested in clinical trials are strongly influenced by the balance of EGFR and PDGFRA activation in individual cells, which is heterogeneous at baseline. 28831081 2017
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.400 Biomarker disease BEFREE Genomic mapping has driven the classification of glioblastoma into distinct molecular subclasses, but mechanisms that regulate tumor subclass phenotypes are only now emerging.In this issue of Cancer Cell, Lu et al. describe a phenotypic switch from PDGFRA-enriched "proneural" to EGFR-enriched "classical" features in glioblastoma upon ablation of Olig2. 27165737 2016
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.400 Biomarker disease BEFREE Surprisingly, we observed the induction of anti-apoptotic proteins and compensatory oncogenic signals such as EDN1, EDNRB, PRKCB1, PDGF-C and PDGF-D. To conclude, we hypothesize that the newly discovered PDGFRα/Stat3/Rb1 regulatory axis might represent a potential therapeutic target for GBM treatment. 27344175 2016
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.400 Biomarker disease BEFREE PDGFRA amplification was more common in cases with GBM than with PNET morphology (36 vs. 5 %, respectively), while CCND2 amplifications showed the opposite trend (5 vs. 27 %). 26482474 2016
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.400 GeneticVariation disease BEFREE Tumor types were characterized by specific broad and focal chromosomal events including focal loss of the INK4A/B locus in glioblastoma and loss of the RB1 gene and amplification of the PDGFRA gene in oligodendrogliomas. 27251041 2016
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.400 Biomarker disease BEFREE Furthermore, forced expression of miR-129-2 repressed the expression of major oncogenic genes such as PDGFRa and Foxp1 in GBMs. 26320507 2015
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.400 Biomarker disease BEFREE The extrachromosomal nature of ALEMs explains the observed drastic changes in the amounts of mutated oncogenes (like EGFR or PDGFRA) in glioblastoma in response to environmental changes. 25471132 2014
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.400 Biomarker disease BEFREE We find evidence of regional mutational heterogeneity in multiple tumors, including mutations in TP53 and RB1 in an anaplastic oligodendroglioma and amplifications in PDGFRA and KIT in two glioblastomas (GBMs). 25608559 2014
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.400 Biomarker disease BEFREE A younger age at diagnosis and better clinical outcome in glioblastoma patients is only seen when PDGFRA and KIT are co-amplified. 23990986 2013
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.400 Biomarker disease BEFREE We showed that machine-based classification of GBMs with high oligodendroglioma component uncovered a set of tumors with strong associations with PDGFRA amplification, proneural transcriptional class, and expression of the oligodendrocyte signature genes MBP, HOXD1, PLP1, MOBP and PDGFRA. 24236209 2013
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.400 Biomarker disease BEFREE Glioblastomas with a proneural expression signature are characterized by frequent IDH1 mutations (i.e. genetic hallmarks of secondary glioblastomas) and PDGFRA (platelet-derived growth factor receptor-α) amplification. 23242283 2013
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.400 Biomarker disease BEFREE PDGFRA amplification is common in pediatric and adult high-grade astrocytomas and identifies a poor prognostic group in IDH1 mutant glioblastoma. 23438035 2013
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.400 Biomarker disease BEFREE Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response. 22323597 2012
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.400 AlteredExpression disease BEFREE We found that PDGFRα is expressed only in a subset of GBMs, while PDGFRβ is more commonly expressed in tumors but is preferentially expressed by self-renewing tumorigenic GBM stem cells (GSCs). 22661233 2012
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.400 Biomarker disease BEFREE Taken together, this study identifies Dyn2 as an effector that mediates PDGFRα-SHP-2-induced glioma tumor growth and invasion, suggesting that targeting the PDGFRα-SHP-2-Dyn2 pathway may be beneficial to patients with malignant glioblastomas. 21996738 2012